Effects of continuous venovenous hemofiltration on the pharmacology of carperitide, a recombinant human atrial natriuretic peptide

Circulation Journal

Volumn 74, Issue 9, 2010, Pages 1888-1894

  Takahashi, Ryoko ^a   Uchiyama, Akinori ^b   Iguchi, Naoya ^b   Mashimo, Takashi ^b   Fujino, Yuji ^b  

^a OSAKA UNIVERSITY HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Carperitide; Continuous venovenous hemofiltration; Human atrial natriuretic peptide

Indexed keywords

ATRIAL NATRIURETIC FACTOR ALPHA; CYCLIC GMP;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTINUOUS HEMOFILTRATION; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; HEART RATE; HUMAN; MEAN ARTERIAL PRESSURE; METABOLIC CLEARANCE RATE; PLASMA CLEARANCE;

ACUTE KIDNEY INJURY; ADULT; AGED; AGED, 80 AND OVER; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CYCLIC GMP; HEART FAILURE; HEMOFILTRATION; HUMANS; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 77956113629     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0725     Document Type: Article

References (21)

1. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 2006; 27: 47-72.
2. Mills RM, LeJemtel TH, Horton DP, Liang C, Lang R, Silver MA, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: A randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 1999; 34: 155-162.
3. Sezai A, Shiono M, Orime Y, Hata H, Hata M, Negishi N, et al. Low-dose continuous infusion of human atrial natriuretic peptide during and after cardiac surgery. Ann Thorac Surg 2000; 69: 732-738.
4. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000; 343: 246-253.
5. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): Two randomised trials. Lancet 2007; 370: 1483-1493.
6. Hata N, Seino Y, Tsutamoto T, Hiramitsu S, Kaneko N, Yoshikawa T, et al. Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: The PROTECT multicenter randomized controlled study. Circ J 2008; 72: 1787-1793.
7. Nomura F, Kurobe N, Mori Y, Hikita A, Kawai M, Suwa M, et al. Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide effects observed through monitoring dyspnea in acute decompensated heart failure study. Circ J 2008; 72: 1777-1786.
8. Joannidis M. Continuous renal replacement therapy in sepsis and multisystem organ failure. Semin Dial 2009; 22: 160-164.
9. Asahi Kasei Kuraray Medical. Panflow APF-10S. [Internet]. Tokyo: Asahi Kasei Kuraray Medical, c2007-2009. http://mmxkrmkorrffxrrfroffkoot.asahi-med.swl.med-host.com/medical/iryou/restricted/crrt/panflo_apf_s.html (accessed 10 December, 2009).
10. Florkowski CM, Richards AM, Espiner EA, Yandle TG, Frampton C. Renal, endocrine, and hemodynamic interactions of atrial and brain natriuretic peptides in normal man. Am J Physiol 1994; 266: R1244-R1250.
11. Yandle TG, Richards AM, Nicholls MG, Cuneo R, Espiner EA, Livesey JH. Metabolic clearance rate and plasma half life of alphahuman atrial peptide in man. Life Sci 1986; 38: 1827-1833.
12. Kimura K, Yamaguchi Y, Horii M, Kawata H, Yamamoto H, Uemura S, et al. ANP is cleared much faster than BNP in patients with congestive heart failure. Eur J Clin Pharmacol 2007; 63: 699-702.
13. Tonolo G, McMillan M, Polonia J, Pazzola A, Montorsi P, Soro A, et al. Plasma clearance and effects of α-hANP infused in patients with end-stage renal failure. Am J Physiol 1988; 254: F895-F899.
14. Os I, Nordby G, Lyngdal PT, Eide I. Plasma vasopressin, catecholamines and atrial natriuretic factor during hemodialysis and sequential ultrafiltration. Scand J Urol Nephrol 1993; 27: 93-99.
15. Alarabi AA, Hansell P, Wikström B, Danielson BG. Plasma atrial natriuretic factor (αANP) during hemodialysis (HD) and hemofiltration. Scand J Urol Nephrol 1991; 25: 65-69.
16. Heintz B, Königs F, Dakshinamurty KV, Kierdorf H, Gladziwa U, Kirsten R, et al. Response of vasoactive substances to intermittent ultrafiltration in normotensive hemodialysis patients. Nephron 1993; 65: 266-272.
17. Osajima A, Okazaki M, Kato H, Anai H, Tsuda Y, Segawa K, et al. Clinical significance of natriuretic peptides and cyclic GMP in hemodialysis patients with coronary artery disease. Am J Nephrol 2001; 21: 112-119.
18. Minami H, Yasu T, Tagawa T, Yamakawa K, Ueda S. Slower onset of vasodilating action of brain natriuretic peptide (BNP) compared to atrial natriuretic peptide (ANP) in human forearm resistant vessels. Eur J Clin Pharmacol 2008; 64: 859-862.
19. Ricci Z, Garisto C, Morelli S, Di Chiara L, Ronco C, Picardo S. Brain natriuretic peptide is removed by continuous veno-venous hemofiltration in pediatric patients. Interact Cardiovasc Thorac Surg 2009; 9: 33-36.
20. Honore PM, Joannes-Boyau O, Boer W, Collin V. High-volume hemofiltration in sepsis and SIRS: Current concepts and future prospects. Blood Purif 2009; 28: 1-11.
21. Naka T, Jones D, Baldwin I, Fealy N, Bates S, Goehl H, et al. Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: A case report. Crit Care 2005; 9: R90-R95.